Leutetium-DOTATATE is a form of radioactive targeting therapy that combines DOTATATE, a somatostatin analogue and the radionuclide is Leutetium-177.  When the medication is infected into the blood stream, the drug homes in to the neuroendocrine tumor and upon binding to the cancer cell, the leutetium177 will release radiation to kill the cancer cells.